Exubera: first inhaled insulin for the management of diabetes
نویسندگان
چکیده
منابع مشابه
Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
INTRODUCTION Inadequate glycemic control contributes to the development and progression of complications, which are associated with a significant economic burden on healthcare systems. However, optimal glycemic control is difficult to sustain with oral antidiabetic agents and adherence to intensive insulin regimens is compromised by patient compliance to multiple daily injections. Therefore, al...
متن کاملAn assessment of eligibility for inhaled insulin (Exubera): the Fremantle Diabetes Study.
The product information (1) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV1) 70% of that predicted for age, sex, and height should not start Exubera. In those exhibiting 20% decline in FEV1 during follow-up, Exubera should be disc...
متن کاملWill availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the Real World trial
BACKGROUND Common deterrents to insulin therapy for both physicians and patients are the complexity and burden of daily injections. In January 2006, the first inhaled human insulin (INH, Exubera (insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) in the United States and European Union. Resu...
متن کاملInhaled human insulin (Exubera®): clinical profile and patient considerations
Inhaled human insulin (Exubera) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides equivalent HbA1c control. As a monotherapy o...
متن کاملInhaled human insulin (Exubera(®)): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus.
Exubera(®) (EXU, insulin human [rDNA origin]) is the first inhaled insulin approved for the treatment of diabetes in adults. Its pharmacokinetic properties make it suitable as therapy for postprandial glycemia. Clinical trials have demonstrated equal efficacy with short-acting subcutaneous regular and analog insulin in both Type 1 and 2 diabetes, and have also shown that it has value as adjunct...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prescriber
سال: 2007
ISSN: 0959-6682,1931-2253
DOI: 10.1002/psb.39